India is interesting to hear, not only because it so desperately needs some help, but because it very early approved Itolizumab. Granted, the was made by Biocon, an Indian firm, but that does at least indicate a willingness by the nation to go their own way, and not mimic the FDA with-all-these-ponies-there-must-be-some-horseshit approach.

If India wanted to approve Leron, all the vials the company can produce could go to that one nation in a fraction of an eyeblink. Which is great for us shareholders, but I would still wish that the US and Europe (where I live) had a shot at it too.